GAVI
in talks with China's Sinopharm, other vaccine makers for COVAX doses
Send a link to a friend
[May 10, 2021]
GENEVA (Reuters) -The GAVI Vaccine Alliance is in talks with COVID-19
vaccine manufacturers including China's state-owned Sinopharm to expand
the COVAX pipeline and secure doses for distribution, a GAVI spokeswoman
said on Monday.
|
Sinopharm
received emergency use listing from the World Health Organization
(WHO) last Friday, making it eligible for the COVAX programme and
bolstering Beijing's push for a bigger role in inoculating the
world.
COVAX, run jointly by GAVI and the WHO to provide doses to the
world's poorest people, has hit major supply problems. To date the
AstraZeneca shot made by the Serum Institute of India account for
most doses rolled out, but authorities there have restricted exports
because of India's massive epidemic.
"GAVI, on behalf of the COVAX Facility, is in dialogue with several
manufacturers, including Sinopharm, to expand and diversify the
portfolio further and secure access to additional doses for Facility
participants," a spokeswoman told Reuters on Monday in response to a
query.
![](http://archives.lincolndailynews.com/2021/May/10/images/ads/current/charrons_bch041713.png)
"Following on from the new announcements on Moderna and Novavax, we
will continue to provide updates on any new deals in due course,"
she added, referring to the U.S. vaccine makers.
[to top of second column] |
![](http://archives.lincolndailynews.com/2021/May/10/images/ads/current/stclara_lda_SPONSOR_090519.png)
Novavax Inc said on Thursday it has agreed with GAVI to manufacture
and distribute 350 million doses of its COVID-19 vaccine to
countries participating under COVAX.
Moderna will supply 34 million doses of its COVID-19 vaccine this
year to the COVAX programme, with 466 million available next year,
Gavi said last week.
GAVI, appealing for full financing of COVAX, said on Monday that it
would require an additional $1.7 billion at the least by June to
lock in supplies for 2021 and early 2022.
(Reporting by Stephanie Nebehay; Editing by Jan Harvey and Louise
Heavens)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |